WAF-1 (p21) and p53 polymorphisms in breast cancer.
Authors
Keshava CKC; Frye BL; Wolff MS; Weston A
Source
Proceedings of the 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 1-5, 2000, Philadelphia, PA: American Association for Cancer Research, 2000 Mar; 41:129
Link
NIOSHTIC No.
20020975
Abstract
Previous studies have indicated that certain p53 polymorphisms confer an increased risk of breast cancer (ORs and 95% CIS = 2.9, 1.4 - 6.3 Carcinogenesis 17: 1313, 1996; 2.5, 1.3 - 4.8 Cancer Epidemiology, Biomarkers and Prevention 6: 105, 1997; 1.5, 1.1 - 2.0, Anticancer Research 18: 2095, 1998). p53 is a transcription factor for Waf-1/p21 a cyclin-dependent kinase inhibitor, which is also polymorphic. To test the hypothesis that minor variants (F = 0.10 Caucasians, 0.27 Latinas, 0.34 African Americans) of a codon 31 polymorphism of Waf-1 are involved in this process, genotypes were determined by PCR/RFLP for 355 women (122 cases and 233 controls) enrolled in breast cancer case-control study. No increased breast cancer risk was associated with inheritance of minor variants of Waf-1 (OR = 1.1, 95% Cl = 0.7 - 1.6). Similarly, analysis by both race and menopausal status was unable to find any association. Finally, despite an increased risk for Caucasians associated with the p53 genotype (CEBP 1997), no risk was found to be associated with Waf-1 alleles independently or in combination with p53 alleles (OR = 1.1, 95Cl = 0.3 - 4.7).
Keywords
Breast cancer; Cancer; Cancer rates; Demographic characteristics; Racial factors; Risk factors; Risk analysis; Case studies; Age factors; Sex factors
Publication Date
20000301
Document Type
Abstract; Conference/Symposia Proceedings
Fiscal Year
2000
ISSN
0197-016X
NIOSH Division
HELD
Source Name
Proceedings of the 91st Annual Meeting of the American Association for Cancer Research
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.